|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Increased expression of receptor activator of NF-kappaB ligand (RANKL) , its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients 显示文摘 | Franchimont N Reenaers C Lambert C | | Clinical & Experimental \ Immunology0，138，3： | 1 |
| 2 | Role of endos- copy,cross-sectional imaging and biomarkers in CrohnPs disease monitoring显示文摘 | Benitez JM Meuwis MA Reenaers C | 2013 | Gut2013，62，12： | 1 |
| 3 | A patient who survived total colonic ulcerative colitis surinfected by cytomegalovirus complicated by toxic megacolon and disseminated intravascular coagulation显示文摘 | Laurent S Reenaers C Detroz B | 2005 | Acta Gastroenterol Belg2005，68，2： | 1 |
| 4 | Current directions of biologic thera- pies in inflammatory bowel disease 显示文摘 | Reenaers C Louis E Belaiche J | 2010 | Therap Adv Gastroenterol2010，3，： | 1 |
| 5 | Genetics of ulcerative colitis:The come - back of interleukin 10 显示文摘 | Louis E Libioulle C Reenaers C | 2009 | Gut2009，58，9： | 1 |
| 6 | Increased expression of receptor activator of NF-kappa B ligand(RANKL),its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients显示文摘 | Franchimont N Reenaers C Lambert C | 2004 | Clin Exp Immunol2004，138，3： | 1 |
| 7 | Are we giving biologics too much time? When should we stop treatment?显示文摘The optimal duration of biological treatment, particu- larly anti-TNF, in inflammatory bowel disease (IBD) is a very important question both for patients and physicians. There is no published evidence to clearly and definitely answer this question. However data on natural history of IBD, long term safety of biologics, immunosuppressors (IS) cessation and some preliminary studies on biologics cessation may help us to discuss this topic. The decision to stop a biological treatment is currently based on a compromise between the benefits and risks associated with the prolongation of this treat- ment. IBD, more particularly CD, are characterized by the development of complications and the need for recurrent hospitalizations and surgeries in approximately 2/3 of cases. In these patients potentially in need of biological treatments, it is probable that, as it has been demonstrated for IS, the longer a stable remission has be achieved under treatment, the lower the risk of relapse is after treatment cessation. Further prospective studies should now aim at disclosing patient characteristics associated with a low risk of relapse to implement this strategy. | Edouard Louis J Belaiche C Reenaers | 2008 | World Journal of Gastroenterology2008，14，36： | 1 |
| 8 | Increased expression of receptor activator of NF-kappaB ligand (RANKL) , its receptor RANK and its decoy receptor osteoprote-gerin in the colon of crohnps disease patients显示文摘 | Franchimont N Reenaers C Lambert C | 2004 | Clin Exp Immunol2004，138，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员